Artivion, Inc.
Artivion, Inc. is a medical device company focused on cardiac and vascular surgery, with its primary political exposure stemming from $449.9K in annual physician payments and a single congressional trader executing two sales.
BusinessWhat AORT does
Artivion, Inc. develops, manufactures, and distributes medical devices and implantable biological tissues for cardiac and vascular surgery. Its revenue is derived from the sale of products like surgical patches, valves, and stent grafts to hospitals and surgical centers. The company operates in the highly regulated medical device sector under FDA oversight.
12 months past · 3 months futureAORT activity timeline
Executive Branch ConflictsAORT held by Trump-administration officials
Lifetime Government AwardsAORT federal contracts
AORT doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Politicians Trading AORTMembers of Congress with recent AORT positions
Congressional TradesWho in Congress is trading AORT
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting AORTLive legislation impacting this stock
Political ProfileWhere AORT sits in Washington
[object Object]
STRUCTURAL: High regulatory density (score 85) from FDA/CMS oversight, but no lobbying spend (`get_political_influence.lobbying.total_income` = 0) or federal contracts (`get_government_precedent.federal_contracts_summary` is null). EVIDENTIARY: Significant physician payments ($449.9K in 2024 per `get_political_influence.doctor_payments`) indicate commercial engagement, countered by a single congressional trader's sales and minimal insider buying (one $38K purchase in 180 days per `Recent corp insider Form 4 buys`). Net: Regulatory risk is inherent, but direct political engagement is minimal and trading signals are weak/negative.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Heightened FDA scrutiny and potential reimbursement changes from CMS affecting medical device approvals and pricing.FDA, CMS"Implied from sector classification and high `regulatory_density_score`; no direct carveouts in `Recent bill_carveouts`."
Regulatory opportunities
-
Potential for expedited review pathways or favorable coverage decisions for novel cardiac/vascular devices.FDA, CMS"Implied from sector; no direct evidence in provided RPC fields (`get_government_precedent.federal_contracts_summary` is null)."
Capitol Hill AlliesChampions & critics
Congressional champions
- No specific congressional champions identified.
Congressional critics
- Unknown Unknown
Live signals + predictions for AORT — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades AORT
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord